Replies to post #75138 on Biotech Values

[wallstarb]

Actually I was talking about the problem TELK had with their breast cancer study and the issues regarding toxicity. Then they didnt halt the trials when it was found out that patients were having issues with the drug. It might not have been Telcyta - I never followed TELK to be honest.

Now as far as the prodrug - alkylators have been around for a long time and are a commonly accepted chemo

[wallstarb]

<I think we're not communicating well in this regard. The problem was exactly that TELK's drug did *not* kill cancer at all!>

OK so it's your position that alkylators don't work. Or is it that Telik's didn't. I guess your supposition just didn't make any sense to me because TELK's drug was nothing like Thresholds aside from they were both using a prodrug that after its metabalized was an alkylator. Telcytas problem seems to lay in the MoA from what I can gather from my reading about it - I haven't spent more then a few hours so maybe I missed something.

Threshold didn't comment much on TELK's drug or trial - but they said aside from the prodrugs being alkylators there weren't anywhere near being similar. I think my question is what do you think is similar? I'm curious as you made them seem as if they were very similar, so perhaps you are seeing something I'm oblivious to.

I can't say what Telcyta was metabalized into, but TH-302 prodrug is a phosphoramidate-based, DNA-crosslinking, bis-alkylator mustards and have long been used successfully in cancer chemotherapy and include the prodrugs ifosfamide and cyclophosphamide. ifosfamide has a long track record and a well proven history of efficacy.